The Latest Advancement on Diagnosis and Treatment of Liver Malignant Tumor with Guideline of Minimally Invasive Concept_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

王凤军 , 刘连新 , 张志程 , 李龙 , 田蓝天

Corresponding author：

Keywords：

微创观念; 肝脏恶性肿瘤; 进展

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 王凤军,刘连新,张志程,李龙,田蓝天. The Latest Advancement on Diagnosis and Treatment of Liver Malignant Tumor with Guideline of Minimally Invasive Concept. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2010, 17(3): 219-223. doi: Copy

1.	董家鸿. 肝细胞癌治疗理念与策略的转变 [J]. 中华消化外科杂志, 2009; 8(2): 8587.
2.	Brooke BS, Nathan H, Pawlik TM. Trends in the quality of highly cited surgical research over the past 20 years [J]. Ann Surg, 2009; 249(1): 162167.
3.	Clavien PA, Petrowsky H, DeOliveira ML, et al. Strategies for safer liver surgery and partial liver transplantation [J]. N Engl J Med, 2007; 356(15): 15451559.
4.	董家鸿, 黄志强. 精准肝切除-21世纪肝脏外科新理念 [J]. 中华外科杂志, 2009； 47(21): 16011605.
5.	Ueno S, Kubo F, Sakoda M, et al. Efficacy of anatomic resection vs nonanatomic resection for small nodular hepatocellular carcinoma based on gross classification [J]. J Hepatobiliary Pancreat Surg, 2008; 15(5): 493500.
6.	Lim HK, Choi D, Lee WJ, et al. Hepatocellular carcinoma treated with percutaneous radiofrequency ablation: evaluation with followup multiphase helical CT [J]. Radiology, 2001; 221(2): 447454.
7.	Choi D, Lim HK, Kim SH, et al. Assessment of therapeutic response in hepatocellular carcinoma treated with percutaneous radio frequency ablation: comparison of multiphase helical computed tomography and power Doppler ultrasonography with a microbubble contrast agent [J]. J Ultrasound Med, 2002; 21(4): 391401.
8.	Dromain C, de Baere T, Elias D, et al. Hepatic tumors treated with percutaneous radiofrequency ablation: CT and MR imaging followup [J]. Radiology, 2002; 223(1): 255262.
9.	Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8 510 patients [J]. Gastroenterology, 2006; 131(2): 461469.
10.	Li Q, Wang J, Sun Y, et al. Postoperative transhepatic arterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma: a randomized study with 131 cases [J]. Dig Surg, 2006; 23(4): 235240.
11.	Zhong C, Guo RP, Li JQ, et al. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for stage ⅢA hepatocellular carcinoma [J]. J Cancer Res Clin Oncol, 2009; 135(10): 14371445.
12.	Gish RG, Gordon SC, Nelson D, et al. A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma [J]. Hepatol Int, 2009; 3(3): 480489.
13.	Stampfl U, Stampfl S, Bellemann N, et al. Experimental liver embolization with four different spherical embolic materials: impact on inflammatory tissue and foreign body reaction [J]. Cardiovasc Intervent Radiol, 2009; 32(2): 303312.
14.	Bonomo G, Pedicini V, Monfardini L, et al. Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly sizecalibrated, antiinflammatory microparticles: first clinical experience and oneyear followup [J]. Cardiovasc Intervent Radiol. Published online: 3 December 2009. DOI: 10.1007/s002700099752y.
15.	Beppu T, Iwatsuki M, Okabe H, et al. A new approach to percutaneous transhepatic portal embolization using ethanolamine oleate iopamidol [J]. J Gastroenterol. Published online: 10 October 2009. DOI: 10.1007/s0053500901436.
16.	Khorsandi SE, Kysela P, Valek V, et al. Initial data on a novel endovascular radiofrequency catheter when used for arterial occlusion in liver cancer [J]. Eur Surg, 2009; 41(3): 104108.
17.	Veltri A, Moretto P, Doriguzzi A, et al. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable nonearly hepatocellular carcinoma (HCC) [J]. Eur Radiol, 2006; 16(3): 661669.
18.	Song I, Rhim H, Lim HK, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the diaphragm and gastrointestinal tracts with the use of artificial ascites: safety and technical efficacy in 143 patients [J]. Eur Radiol, 2009; 19(11): 26302640.
19.	Ueno S, Sakoda M, Kubo F, et al. Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria [J]. J Hepatobiliary Pancreat Surg, 2009; 16(3): 359366.
20.	Cheung TT, Ng KK, Poon RT, et al. Tolerance of radiofrequency ablation by patients of hepatocellular carcinoma [J]. J Hepatobiliary Pancreat Surg, 2009; 16(5): 655660.
21.	Becker G, Soezgen T, Olschewski M, et al. Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma [J]. World J Gastroenterol, 2005; 11(39): 61046109.
22.	陈敏山, 张耀军, 李锦清, 等. 经皮射频消融联合瘤内无水酒精注射与单纯射频消融治疗小肝癌的疗效比较 [J]. 中华肿瘤杂志, 2005; 27(10): 623625.
23.	Simonetti RG, Liberati A, Angiolini C, et al. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials [J]. Ann Oncol, 1997; 8(2): 117136.
24.	Ramanathan RK, Belani CP, Singh DA, et al. A phase Ⅱ study of lapatinib in patients with advanced biliary tree and hepatocellular cancer [J]. Cancer Chemother Pharmacol, 2009; 64(4): 777783.
25.	Thomas MB, Morris JS, Chadha R, et al. Phase Ⅱ trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma [J]. J Clin Oncol, 2009; 27(6): 843850.
26.	Philip PA, Mahoney MR, Allmer C, et al. Phase Ⅱ study of Erlotinib (OSI774) in patients with advanced hepatocellular cancer [J]. J Clin Oncol, 2005; 23(27): 66576663.
27.	AbouAlfa GK, Schwartz L, Ricci S, et al. Phase Ⅱ study of sorafenib in patients with advanced hepatocellular carcinoma [J]. J Clin Oncol, 2006; 24(26): 42934300.
28.	Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): Results of a phase Ⅲ randomized placebocontrolled trial (SHARP trial) [J]. J Clin Oncol, 2007; 25: LBA1.
29.	Sun W, Haller DG, Mykulowycz K, et al. Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): A phase Ⅱ study. 2007 ASCO Annual Meeting Proceedings Part Ⅰ [J]. J Clin Onco, 2007; 25(Suppl 18): 4574.
30.	Thomas MB, Chadha R, Iwasaki M, et al. The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC) [J]. J Clin Oncol, 2007; 25(Suppl 18): 214s.
31.	Louafi S, Boige V, Ducreux M, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase Ⅱ study [J]. Cancer, 2007; 109(7): 13841390.

1. 董家鸿. 肝细胞癌治疗理念与策略的转变 [J]. 中华消化外科杂志, 2009; 8(2): 8587.
2. Brooke BS, Nathan H, Pawlik TM. Trends in the quality of highly cited surgical research over the past 20 years [J]. Ann Surg, 2009; 249(1): 162167.
3. Clavien PA, Petrowsky H, DeOliveira ML, et al. Strategies for safer liver surgery and partial liver transplantation [J]. N Engl J Med, 2007; 356(15): 15451559.
4. 董家鸿, 黄志强. 精准肝切除-21世纪肝脏外科新理念 [J]. 中华外科杂志, 2009； 47(21): 16011605.
5. Ueno S, Kubo F, Sakoda M, et al. Efficacy of anatomic resection vs nonanatomic resection for small nodular hepatocellular carcinoma based on gross classification [J]. J Hepatobiliary Pancreat Surg, 2008; 15(5): 493500.
6. Lim HK, Choi D, Lee WJ, et al. Hepatocellular carcinoma treated with percutaneous radiofrequency ablation: evaluation with followup multiphase helical CT [J]. Radiology, 2001; 221(2): 447454.
7. Choi D, Lim HK, Kim SH, et al. Assessment of therapeutic response in hepatocellular carcinoma treated with percutaneous radio frequency ablation: comparison of multiphase helical computed tomography and power Doppler ultrasonography with a microbubble contrast agent [J]. J Ultrasound Med, 2002; 21(4): 391401.
8. Dromain C, de Baere T, Elias D, et al. Hepatic tumors treated with percutaneous radiofrequency ablation: CT and MR imaging followup [J]. Radiology, 2002; 223(1): 255262.
9. Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8 510 patients [J]. Gastroenterology, 2006; 131(2): 461469.
10. Li Q, Wang J, Sun Y, et al. Postoperative transhepatic arterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma: a randomized study with 131 cases [J]. Dig Surg, 2006; 23(4): 235240.
11. Zhong C, Guo RP, Li JQ, et al. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for stage ⅢA hepatocellular carcinoma [J]. J Cancer Res Clin Oncol, 2009; 135(10): 14371445.
12. Gish RG, Gordon SC, Nelson D, et al. A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma [J]. Hepatol Int, 2009; 3(3): 480489.
13. Stampfl U, Stampfl S, Bellemann N, et al. Experimental liver embolization with four different spherical embolic materials: impact on inflammatory tissue and foreign body reaction [J]. Cardiovasc Intervent Radiol, 2009; 32(2): 303312.
14. Bonomo G, Pedicini V, Monfardini L, et al. Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly sizecalibrated, antiinflammatory microparticles: first clinical experience and oneyear followup [J]. Cardiovasc Intervent Radiol. Published online: 3 December 2009. DOI: 10.1007/s002700099752y.
15. Beppu T, Iwatsuki M, Okabe H, et al. A new approach to percutaneous transhepatic portal embolization using ethanolamine oleate iopamidol [J]. J Gastroenterol. Published online: 10 October 2009. DOI: 10.1007/s0053500901436.
16. Khorsandi SE, Kysela P, Valek V, et al. Initial data on a novel endovascular radiofrequency catheter when used for arterial occlusion in liver cancer [J]. Eur Surg, 2009; 41(3): 104108.
17. Veltri A, Moretto P, Doriguzzi A, et al. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable nonearly hepatocellular carcinoma (HCC) [J]. Eur Radiol, 2006; 16(3): 661669.
18. Song I, Rhim H, Lim HK, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the diaphragm and gastrointestinal tracts with the use of artificial ascites: safety and technical efficacy in 143 patients [J]. Eur Radiol, 2009; 19(11): 26302640.
19. Ueno S, Sakoda M, Kubo F, et al. Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria [J]. J Hepatobiliary Pancreat Surg, 2009; 16(3): 359366.
20. Cheung TT, Ng KK, Poon RT, et al. Tolerance of radiofrequency ablation by patients of hepatocellular carcinoma [J]. J Hepatobiliary Pancreat Surg, 2009; 16(5): 655660.
21. Becker G, Soezgen T, Olschewski M, et al. Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma [J]. World J Gastroenterol, 2005; 11(39): 61046109.
22. 陈敏山, 张耀军, 李锦清, 等. 经皮射频消融联合瘤内无水酒精注射与单纯射频消融治疗小肝癌的疗效比较 [J]. 中华肿瘤杂志, 2005; 27(10): 623625.
23. Simonetti RG, Liberati A, Angiolini C, et al. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials [J]. Ann Oncol, 1997; 8(2): 117136.
24. Ramanathan RK, Belani CP, Singh DA, et al. A phase Ⅱ study of lapatinib in patients with advanced biliary tree and hepatocellular cancer [J]. Cancer Chemother Pharmacol, 2009; 64(4): 777783.
25. Thomas MB, Morris JS, Chadha R, et al. Phase Ⅱ trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma [J]. J Clin Oncol, 2009; 27(6): 843850.
26. Philip PA, Mahoney MR, Allmer C, et al. Phase Ⅱ study of Erlotinib (OSI774) in patients with advanced hepatocellular cancer [J]. J Clin Oncol, 2005; 23(27): 66576663.
27. AbouAlfa GK, Schwartz L, Ricci S, et al. Phase Ⅱ study of sorafenib in patients with advanced hepatocellular carcinoma [J]. J Clin Oncol, 2006; 24(26): 42934300.
28. Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): Results of a phase Ⅲ randomized placebocontrolled trial (SHARP trial) [J]. J Clin Oncol, 2007; 25: LBA1.
29. Sun W, Haller DG, Mykulowycz K, et al. Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): A phase Ⅱ study. 2007 ASCO Annual Meeting Proceedings Part Ⅰ [J]. J Clin Onco, 2007; 25(Suppl 18): 4574.
30. Thomas MB, Chadha R, Iwasaki M, et al. The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC) [J]. J Clin Oncol, 2007; 25(Suppl 18): 214s.
31. Louafi S, Boige V, Ducreux M, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase Ⅱ study [J]. Cancer, 2007; 109(7): 13841390.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

The Latest Advancement on Diagnosis and Treatment of Liver Malignant Tumor with Guideline of Minimally Invasive Concept

Abstract Full text Figures/Tables Video References Cited by

Format

Content